Key result
Cangrelor for OHCA patients requiring PCI yields ~10% modeled cost savings over five years.
Why the study?
To estimate the affordability and budget impact in the UK of introducing cangrelor within the licenced OHCA population undergoing PCI.
Does introducing cangrelor reduce healthcare costs in out-of-hospital cardiac arrest patients requiring percutaneous coronary intervention who cannot take oral P2Y12 inhibitors?
Does introducing cangrelor reduce healthcare costs in out-of-hospital cardiac arrest patients requiring percutaneous coronary intervention who cannot take oral P2Y12 inhibitors?
Answers are grounded in this paper and cite their sources.
Introducing intravenous cangrelor for OHCA patients undergoing PCI who cannot take oral P2Y12 inhibitors is projected to be cost-saving for the UK NHS, primarily by reducing bleeding-related hospital length of stay.
Background: Cangrelor is an intravenous, reversible P2Y12 inhibitor indicated for the reduction of thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure, and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable (for example, in the out-of-hospital cardiac arrest [OHCA] population). Objective: This study aimed to estimate the affordability and budget impact, in the United Kingdom, of introducing cangrelor within the licenced OHCA population. Methods: A budget impact model was developed to estimate the impact of introducing cangrelor to hospitals over 5 years. Efficacy (thrombotic events) and safety (bleeding events) data were based on clinical trials, cost data (2021/22 GBP), literature, NHS reference costs and British National Formulary data. Comparators were glycoprotein IIb/IIIa inhibitors and aspirin in combination with heparin, reflecting current treatments used in UK centres for the target population. Cangrelor uptake was estimated as 50% in Year 1, 75% in Year 2, and 100% in Years 3-5. The OHCA population was estimated from the British Cardiovascular Intervention Society National Audit 2021/22. Results: Over 5 years, cangrelor leads to modelled cost savings of £2,709,853 (-9.84%), varying from £322,218 in Year 1 (-5.85%) to £636,150 (-11.55%) in Year 5). This is driven by approximately 6,882 hospital days being avoided over 5 years due to fewer bleeding events. Conclusion: Cangrelor for OHCA patients who cannot take oral P2Y12 inhibitors may lead to cost savings in the UK.
No takes yet. Share an insight, caveat, or question.
Modi et al. (2025) studied Out-of-hospital cardiac arrest requiring percutaneous coronary intervention (n=15,154). Cangrelor vs. Glycoprotein IIb/IIIa inhibitors and aspirin in combination with heparin was evaluated on Budget impact over 5 years (-£2,709,853 (-9.84%)). Introducing cangrelor for out-of-hospital cardiac arrest patients requiring percutaneous coronary intervention in the UK leads to modeled cost savings of £2,709,853 over 5 years.
Synapse has enriched 10 related papers. Consider them for comparative context: